

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Acticarp 50 mg/ml Solution for Injection for Cattle  
BE/LU/NL: Acticarp Cattle 50 mg/ml oplossing voor injectie voor runderen  
ES: Carprovet 50 mg/ml Solución inyectable para bovino

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Per ml:

**Active substance:**

Carprofen                      50 mg

**Excipients:**

Ethanol anhydrous              0.1 ml

For a full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Solution for Injection  
Clear, pale straw yellow solution.

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Cattle.

#### **4.2 Indications for use, specifying the target species**

The product is indicated as an adjunct to antimicrobial therapy to reduce clinical signs in acute infectious respiratory disease and acute mastitis in cattle.

#### **4.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals suffering from cardiac, hepatic or renal impairment.

Do not use in animals suffering from gastro-intestinal ulceration or bleeding.

Do not use where there is evidence of a blood dyscrasia.

#### **4.4 Special warnings for each target species**

None.

#### **4.5 Special precautions for use**

i. Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided.

Do not exceed the stated dose or the duration of treatment.  
Do not administer other NSAID's concurrently or within 24 hours of each other.

As NSAID therapy can be accompanied by GI or renal impairment, adjunctive fluid therapy should be considered especially in the case of acute mastitis treatment.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals

Carprofen, in common with other NSAIDs, has been shown to exhibit photosensitising potential in laboratory studies.  
Avoid skin contact with the product. Should this occur, wash the affected areas immediately.

#### **4.6 Adverse reactions (frequency and seriousness)**

Studies in cattle have shown that a transient local reaction may form at the site of the injection.

#### **4.7 Use during pregnancy, lactation or lay**

In the absence of any specific studies in pregnant cattle, use only after a risk/benefit assessment has been performed by the attending veterinary surgeon.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No significant drug interactions have been reported for carprofen. During clinical studies in cattle four different antibiotic classes were used, macrolides, tetracyclines, cephalosporins and potentiated penicillins without known interactions. However, in common with other NSAIDs, carprofen should not be administered simultaneously with another product of the NSAID or glucocorticoid class. Animals should be carefully monitored if carprofen is administered simultaneously with an anticoagulant.

NSAID's are highly bound to plasma proteins and may compete with other highly bound drugs, such that concomitant administration may result in toxic effects.

#### 4.9 Amounts to be administered and administration route

The product should be given as a single subcutaneous or intravenous injection at a dosage of 1.4 mg carprofen/kg body weight (1 ml/35 kg) in combination with antibiotic therapy, as appropriate.

#### 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In clinical studies, no adverse signs were reported after intravenous and subcutaneous administration of up to 5 times the recommended dose.

There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAID's, should be applied.

#### 4.11 Withdrawal period(s)

Meat and offal: 21 days  
Milk: zero hours

### 5. PHARMACOLOGICAL PROPERTIES

**Pharmacotherapeutic group:** Anti-inflammatory and Anti-rheumatic products, non-steroids.

**ATCvet code:** QM01AE91

#### 5.1 Pharmacodynamic properties

Carprofen is a member of the 2-arylpropionic acid group of non-steroidal anti-inflammatory drugs (NSAID's), and possesses anti-inflammatory, analgesic and antipyretic activity.

Carprofen, like most other NSAID's is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However, the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. The precise mode of action is unclear.

Studies have shown that carprofen has potent antipyretic activity and significantly reduces the inflammatory response in lung tissue in cases of acute, pyrexia infectious respiratory disease in cattle. Studies in cattle with experimentally induced acute mastitis have shown that carprofen administered intravenously has potent antipyretic activity and improves heart rate and rumen function.

#### 5.2 Pharmacokinetic particulars

##### Absorption:

Following a single subcutaneous dose of 1.4 mg carprofen/kg the maximum plasma concentration ( $C_{max}$ ) of 15.4 µg/ml was reached after ( $T_{max}$ ) 7-19 hours.

Distribution:

The highest carprofen concentrations are found in bile and plasma and more than 98% of carprofen is bound to plasma proteins. Carprofen was well distributed in the tissues with the highest concentrations found in kidney and liver followed by fat and muscle.

Metabolism:

Carprofen (parent) is the main component in all tissues. Carprofen (parent compound) is slowly metabolised primarily by ring hydroxylation, hydroxylation at the  $\alpha$ -carbon and by conjugation of the carboxylic acid group with glucuronic acid. The 8-hydroxylated metabolite and unmetabolized carprofen predominate in the faeces. Bile samples are comprised of conjugated carprofen.

Elimination:

Carprofen has a plasma elimination half-life of 70 hours. Carprofen is primarily excreted in the faeces, indicating that the biliary secretion plays an important role.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Ethanol anhydrous  
Macrogol 400  
Poloxamer 188  
Ethanolamine  
Water for injection

### **6.2 Incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years  
Shelf-life after first opening the immediate packaging: 28 days

### **6.4 Special precautions for storage**

No special precautions for storage.

### **6.5 Nature and composition of immediate packaging**

50 ml amber glass (Type I) vial closed with Flurotec (coated chlorobutyl) rubber stopper and aluminium flip off. One vial in a carton box.

**6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local/national requirements.

**7. MARKETING AUTHORISATION HOLDER**

Ecuphar NV  
Legeweg 157-i  
B-8020 Oostkamp  
Belgium

**8. MARKETING AUTHORISATION NUMBER**

**Vm** 32742/4005

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

**Date:** 09 May 2012

**10. DATE OF REVISION OF THE TEXT**

**Date:** April 2013

Approved: 25/04/2013

A handwritten signature in black ink, appearing to read 'Palton', is located below the approval date.